Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease

Yumin Wang; Shuang Wu; Qiang Li; Weihong Lang; Wenjing Li; Xiaodong Jiang; Zhirong Wan; Jichao Chen; Hongquan Wang

doi:10.3389/fphar.2022.977521

Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease

Front Pharmacol. 2022 Sep 12:13:977521. doi: 10.3389/fphar.2022.977521. eCollection 2022.

Authors

Yumin Wang¹, Shuang Wu², Qiang Li³, Weihong Lang⁴, Wenjing Li³, Xiaodong Jiang⁵, Zhirong Wan⁶, Jichao Chen¹, Hongquan Wang⁷

Affiliations

¹ Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.
² Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, China.
³ Department of Neurology, The Affiliated Hospital of Chifeng University, Chifeng, China.
⁴ Department of Psychological Medicine, The Affiliated Hospital of Chifeng University, Chifeng, China.
⁵ Department of Anatomy, College of Basic Medicine, Chifeng University Health Science Center, Chifeng, China.
⁶ Department of Neurology,Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.
⁷ Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.

Abstract

Epigallocatechin 3-gallate (EGCG), an abundant polyphenolic component derived from green tea extract, possesses versatile bioactivities that can combat many diseases. During the last decade, EGCG was shown to be effective in experimental models of Parkinson's disease (PD). Several experimental studies have suggested that it has pleiotropic neuroprotective effects, which has enhanced the appeal of EGCG as a therapeutic strategy in PD. In this review, we compiled recent updates and knowledge of the molecular mechanisms underlying the neuroprotective effects of EGCG in PD. We focused on the effects of EGCG on apoptosis, oxidative stress, inflammation, ferroptosis, modulation of dopamine production, and the aggregation of α-synuclein. The review highlights the pharmacological features of EGCG and its therapeutic implications in PD. Taken together, the accumulated data indicate that EGCG is a promising neuroprotective compound for the treatment of PD.

Keywords: Parkinson’s disease; apoptosis; epigallocatechin 3-gallate; neuroinflammation; oxidative stress; α-synuclein.

Publication types

Review